(168 days)
No
The summary describes standard image processing and analysis modules for nuclear medicine data. There is no mention of AI, ML, or related concepts, and the performance studies focus on comparisons with previous versions and manual calculations, not on AI/ML model performance metrics.
No
The device is a software suite used to process, display, analyze, and manage medical imaging data; it does not directly treat or prevent a disease or condition.
Yes
Explanation: The "Intended Use / Indications for Use" states that the device provides "software applications used to process, display, analyze and manage nuclear medicine and other medical imaging data." This processing and analysis of medical imaging data is inherently for diagnostic purposes. Additionally, the "Device Description" lists various modules like "Colonic Transit, Remnant Liver, Parathyroid, Dosimetry, Classic DMSA, Oesophageal Transit/Reflux, HIDA, Salivary Gland, Bone3Phase Analysis and Uniformity" which are used to evaluate specific medical conditions, further supporting its role as a diagnostic device.
Yes
The device is described as a "software suite" and its function is to process, display, analyze, and manage medical imaging data. There is no mention of any accompanying hardware components that are part of the device itself. The data is transferred from other workstations or acquisition stations, implying the software operates on existing hardware infrastructure.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states that the software processes, displays, analyzes, and manages medical imaging data transferred from other workstations or acquisition stations. This is focused on interpreting images of the body, not on analyzing samples taken from the body (like blood, urine, tissue, etc.).
- Device Description: The description reinforces that it's a software suite for processing and analyzing imaging data.
- Input Imaging Modality: The input is "nuclear medicine and other medical imaging data," which are images of the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, reagents, or any other components typically associated with IVD devices.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for diagnostic purposes. This device operates on images of the body itself.
N/A
Intended Use / Indications for Use
HERMES Medical Imaging suite that provides software applications used to process, display, analyze and manage nuclear medicine and other medical imaging data transferred from other workstation or acquisition stations.
Product codes
KPS
Device Description
The base product design of Hermes Medical Imaging Suite v5.7 is the same as for the Hermes Medical Imaging Suite v5.6 (K153056). The following modules have been added in this applicatio to Hybrid Viewer NM Processing: Colonic Transit, Remnant Liver, Parathyroid, Dosimetry, Classic DMSA, Oesophageal Transit/Reflux, HIDA, Salivary Gland, Bone3Phase Analysis and Uniformity.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Nuclear medicine and other medical imaging data
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The following comparative tests have been made.
- Hybrid Recon in Hermes Medical Imaging Suite v5.7 has been compared to Hybrid Recon in Medical Imaging Suite v5.6 (K153056). The comparison included 10 subjects, where each subject went through stress&rest myocardial SPECT scan with Tc99m tetrofosmin. The QPS parameters SSS, Stress volume, Stress Area, Stress Defect Area, SRS, Rest Volume, Rest Area, Rest Defect Area were calculated with the Cedar Sinai Application and compared between the applications (Pearson correlation coefficient r between 0.96 to 0.99).
- Hybrid Recon in Hermes Medical Imaging Suite v5.7 has been compared to Hybrid Recon in Medical Imaging Suite v5.6 (K153056). The comparison included studies on Jaszczak phantom and IEC Phantom. The results on the Jaszak Phantom showed an average error between the reconstructed and true activity concentration of -3.5 % with Hybrid Recon in Medical Imaging Suite v5.6 and -1.1 % with Hybrid Recon in Medical Imaging Suite v5.7. The results on the IEC Phantom show that the error of the reconstructed activity concentration is around 5% when the target is large enough. In small targets the partial volume effect lowers the accuracy as expected.
- Classic DMSA in HV NM Processing/Hermes Medical Imaging Suite v5.7 has been compared to the classic DMSA application in Medical Imaging Suite v5.3 (K153056). For relative function values, the maximum% difference between Classic and HybridViewer is
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.
0
November 21, 2017
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Hermes Medical Solutions AB % Joakim Arwidson Quality Manager Skeppsbron 44 Stockholm. 11130 SWEDEN
Re: K171681
Trade/Device Name: HERMES Medical Imaging Suite v5.7 Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS Dated: September 29, 2017 Received: October 26, 2017
Dear Joakim Arwidson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael D. O'Hara
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) FBD K171681
Device Name
HERMES Medical Imaging Suite v5.7
Indications for Use (Describe)
HERMES Medical Imaging suite that provides software applications used to process, display, analyze and manage nuclear medicine and other medical imaging data transferred from other workstation or acquisition stations.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
3
5.0 510 (k) SUMMARY
A. Submitted by:
- Submitters name and address: Hermes Medical Solutions AB Skeppsbron 44 111 30 Stockholm Sweden
. Submitters telephone number
| Phone: | +46 8 19 03 25 |
|---|---|
| Cell: | +46 708 19 03 08 |
| Fax: | +46 8 18 43 54 |
| E-mail: | joakim.arwidson@hermesmedical.com |
● Contact person
Joakim Arwidson Quality Manager Hermes Medical Solutions AB Skeppsbron 44 111 30 Stockholm Sweden
- . Reqistration number 9710645
B. Preparation date:
2017-04-18
C. Proprietary/Trade name, Common name, Classification name:
- Proprietary/Trade name . Hermes Medical Imaging Suite v5.7
- . Common name Image processing systems
- . Classification name Emission Computer Tomography System, Class II, 21CFR892.1200
D. Legally marketed device (predicate device):
Following legally marketed device has been used for comparison.
- Hermes Medical Imaging Suite v5.6 (K153056)
- . Xeleris 3.1 processing and review workstation (K130884)
E. Description of the device that is subject of this premarket notification:
The base product design of Hermes Medical Imaging Suite v5.7 is the same as for the Hermes Medical Imaging Suite v5.6 (K153056). The following modules have been added in this applicatio to Hybrid Viewer NM Processing: Colonic Transit, Remnant Liver, Parathyroid, Dosimetry, Classic DMSA, Oesophageal Transit/Reflux, HIDA, Salivary Gland, Bone3Phase Analysis and Uniformity.
4
F. Intended use:
Hermes Medical Imaging suite that provides software applications used to process, display, analyze and manage nuclear medicine and other medical imaging data transferred from other workstation or acquisition stations.
G. Technological characteristics:
The proposed device Hermes Medical Imaging Suite has the same technological characteristics as the original device and the same indication for use.
H. Testing:
The tests for verification and validation followed Hermes Medical Solutions AB design controlled procedures. The Risk analysis was completed and risk control implemented to mitigate identified hazards. The testing results supports that all the software specifications have met the acceptance criteria.
l. Substantially Equivalent/Conclusions:
The proposed device Hermes Medical Imaging Suite v5.7 and the predicate devices HERMES Medical Imaging Suite v5.6 (K153056) have the same indication for use.
The proposed device will use similar technology and fundamental concepts and operation are also the same, as described in the 510(k) submission.
The following comparative tests have been made.
- Hybrid Recon in Hermes Medical Imaging Suite v5.7 has been compared to Hybrid Recon in Medical Imaging Suite v5.6 (K153056). The comparison included 10 subjects, where each subject went through stress&rest myocardial SPECT scan with Tc99m tetrofosmin. The QPS parameters SSS, Stress volume, Stress Area, Stress Defect Area, SRS, Rest Volume, Rest Area, Rest Defect Area were calculated with the Cedar Sinai Application and compared between the applications (Pearson correlation coefficient r between 0.96 to 0.99).
- -Hybrid Recon in Hermes Medical Imaging Suite v5.7 has been compared to Hybrid Recon in Medical Imaging Suite v5.6 (K153056). The comparison included studies on Jaszczak phantom and IEC Phantom. The results on the Jaszak Phantom showed an average error between the reconstructed and true activity concentration of -3.5 % with Hybrid Recon in Medical Imaging Suite v5.6 and -1.1 % with Hybrid Recon in Medical Imaging Suite v5.7. The results on the IEC Phantom show that the error of the reconstructed activity concentration is around 5% when the target is large enough. In small targets the partial volume effect lowers the accuracy as expected.
- Classic DMSA in HV NM Processing/Hermes Medical Imaging Suite v5.7 has been compared to the classic DMSA application in Medical Imaging Suite v5.3 (K153056). For relative function values, the maximum% difference between Classic and HybridViewer is